Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 20Pain, Postoperative 5Stomach Neoplasms 4Pancreatic Neoplasms 4Neoplasms 4Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Prostatic Neoplasms 3Myoma 3Leiomyoma 3Head and Neck Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Agnosia 3Stomatitis 2Skin Neoplasms 2Postoperative Hemorrhage 2Ovarian Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Non-Hodgkin 2Hemorrhage 2Fatigue 2Colonic Neoplasms 2Chronic Pain 2Carcinoma, Hepatocellular 2Water-Electrolyte Imbalance 1Vulvodynia 1Uterine Cervical Neoplasms 1

Interventions

proxalutamide 1XAV-19 1Standard of Care 1Sodium Chloride 1BNT162 Vaccine 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Severe Acute Respiratory Syndrome × Sodium Chloride × Clear all
NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡